Why the study?
Although thiazolidinediones reduce macrovascular events, their overall cardiovascular benefit must be weighed against an apparent increase in heart failure risk in patients with type 2 diabetes.
This review highlights that while thiazolidinediones increase the risk of heart failure in type 2 diabetes, this may be due to fluid retention unmasking dysfunction rather than direct myocardial toxicity, and is not associated with long-term mortality consequences.
No takes yet. Share an insight, caveat, or question.
Warrants caution with thiazolidinediones in T2DM at HF risk; leaves open diabetic cardiomyopathy mechanisms and safer glucose-lowering options.
Erdmann et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: